Prelude Therapeutics Inc·4

Mar 4, 6:05 PM ET

Combs Andrew 4

4 · Prelude Therapeutics Inc · Filed Mar 4, 2024

Insider Transaction Report

Form 4
Period: 2024-03-01
Combs Andrew
Chief Chemistry Officer
Transactions
  • Award

    Employee Stock Option (right to buy)

    2024-03-01+150,000150,000 total
    Exercise: $4.59Exp: 2034-02-28Common Stock (150,000 underlying)
Footnotes (1)
  • [F1]The stock option vests as to 25% of the total shares on March 1, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Documents

1 file
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT